Octapharma

This study tests a drug called Atenativ in 38 people with a rare inherited condition that raises their risk of blood clots. Participants receive the drug during surgery or childbirth to see if it prevents clots. The goal is to find a safe and effective way to manage this risk dur…

This study looks at whether a medicine called Nuwiq (recombinant factor VIII) can safely prevent bleeding during major surgery in people with severe hemophilia A who are already on a regular treatment called emicizumab. About 28 male patients aged 12 and older will take part. The…

This study tests an intravenous medicine called C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The trial includes 124 participants aged 2 and older who have frequent attacks. The goal is to see if the medic…

This study tests a medicine called Atenativ in 120 adults having heart surgery who do not respond well to the standard blood thinner heparin. The goal is to see if Atenativ can restore heparin's effectiveness during surgery, reducing the need for extra treatments. Participants wi…

This study tests a medicine called Nuwiq (a clotting factor) in women and girls with mild to moderate hemophilia A who are having major surgery. The goal is to see if Nuwiq can successfully control bleeding during and after the operation. About 28 participants will receive the tr…

This study tests a medicine called OCTAPLEX to stop serious bleeding in people taking blood thinners (Factor Xa inhibitors). About 260 adults with major bleeding will get either a low or high dose. The goal is to see which dose works better and is safer. This is a Phase 3 trial, …

This study observes how well Octapharma's FVIII concentrates (Nuwiq, Octanate, Wilate) work in real life for people with severe hemophilia A who have had little or no prior treatment. Researchers will track bleeding events and side effects over time. The goal is to understand the…